EN
SINOVAC's Hepatitis A Vaccine Healive® Approved for Use in Egypt
February 21, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced its inactivated hepatitis A vaccine, Healive®, has been approved by the Egyptian Drug Authority. This marks the company's first direct authorization of a vaccine for market use in Egypt.
As the first and only hepatitis A vaccine from China pre-qualified by the World Health Organization, Healive® has been registered in 24 countries and organizations worldwide. Over 100 million doses of the vaccine have been administrated in more than 30 countries and regions.
Prevention of the hepatitis A virus (HAV) is not included in Egypt's national vaccination schedule. However, it was the most common cause of acute viral hepatitis (AVH) in Egypt between 2014 and 20171, representing 93.4% of the country's confirmed AVH cases. More than half of Egypt's population are already exposed to HAV infection by the age of 15 years.
Healive® offers sustained protection for at least 30 years after full-course immunization, based on statistical modeling2. Abundant evidence regarding the vaccine's safety and immunogenicity can be found in 67 scientific papers based on 44 clinical trials and studies conducted on Healive®. SINOVAC has also collaborated with organizations in South Korea and India to conduct Phase III clinical trials of the vaccine, with the goal of providing protection to more children.
Since the global outbreak of the COVID-19 pandemic, SINOVAC has been an active international partner in Egypt's national healthcare efforts. The Company has offered timely supplies of its COVID-19 vaccine and supported local vaccine production during the height of the pandemic. In 2022, SINOVAC donated an automated complex to further support the development of Egypt's vaccination industry.
SINOVAC's commitment to Egypt's healthcare industry extends beyond the COVID-19 pandemic. With the recent approval of Healive® for market use, the Company can help improve accessibility to hepatitis A vaccines in Egypt and further support local communities in the fight against infectious diseases.
Reference:
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company's website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com